Introduction
• Cutaneous T-Cell Lymphomas are rare, life altering forms of NonHodgkin's Lymphoma presenting in the skin; the most common form, Mycosis Fungoides type Cutaneous Lymphoma (MF-CTCL) affects approximately 20,000 people in the US. Early stage MF-CCTCL is confined to the skin, chronic and slowly progressing • For many patients with MF-CTCL, pruritus is a major concern, significantly affecting quality of life 1 60 patients were randomised to one of 3 treatment arms in a 1:1:1 ratio ▪Remetinostat gel 1% QD ▪Remetinostat gel 0.5% BID ▪Remetinostat gel 1% BID Standard inclusion/exclusion criteria were applied. Concomitant medications which may affect the assessment of pruritus, such as corticosteroids and antihistamines, were prohibited.
The primary endpoint was to assess the effect of remetinostat on CAILS ORR after 6 and 12 months' dosing. Secondary endpoints included assessment of mSWAT, ORR, time to & duration of responses, safety & tolerability, QoL by Skindex-29 and reduction in pruritus severity using the visual analogue scale (VAS). Patients used a VAS to measure pruritus monthly throughout the study. Clinically significant pruritus (CSP) at baseline was defined as a VAS score ≥ 30 mm and a clinically meaningful reduction in pruritus (CMRP) was defined as a ≥ 30mm decrease. A confirmed pruritus response was defined as a clinically meaningful reduction in pruritus (CMRP), observed on 2 consecutive visits, at least 4 weeks apart.  These data demonstrate a potential benefit of topical remetinostat treatment in terms of a clinically meaningful reduction in pruritus, which is an major unmet need in patients with MF-CTCL. Importantly, without the typical systemic effects of oral or intravenous HDACi.  A phase 3 study is planned with pruritus severity reduction (CMRP) a key secondary endpoint Summary Table 2 Change in pruritus severity from baseline 
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